Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot Survey about the perspective on Generation Z among European leaders in Urology: Challenges in educating Generation Z.

Urologia internationalis·2026
Same author

Diagnostic Value of PSMA-PET/CT for the Detection of Pelvic Lymph Node Metastasis in Intermediate and High-Risk Prostate Cancer.

Urologia internationalis·2026
Same author

Surgical Margin Status and Minimal Margin Width in Penile Squamous Cell Carcinoma: Local Recurrence and Survival Outcomes in a Single-Centre Cohort.

Cancers·2026
Same author

European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update.

European urology·2026
Same author

[New guideline for supportive care-what is relevant for urologists?]

Urologie (Heidelberg, Germany)·2026
Same author

[Current diagnostics and treatment of penile cancer].

Urologie (Heidelberg, Germany)·2026

Related Experiment Video

Updated: Jun 20, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Emerging apoptosis agonists for bladder cancer.

Chris Protzel1, Oliver W Hakenberg

  • 1Department of Urology, University of Rostock, 18057 Rostock, Germany.

Expert Opinion on Emerging Drugs
|September 24, 2009
PubMed
Summary

This review explores using apoptosis agonists to improve bladder cancer treatment. Combining these agents with chemotherapy shows promise for advanced bladder cancer, though clinical trials are pending.

Area of Science:

  • Oncology
  • Cancer Research
  • Pharmacology

Background:

  • Bladder cancer is a prevalent and aggressive malignancy.
  • Conventional chemotherapy often fails to cure advanced bladder cancer.
  • Chemoresistance in malignancies frequently involves alterations in apoptotic pathways.

Purpose of the Study:

  • To review current research on apoptosis agonists for bladder cancer.
  • To explore the potential of combining apoptosis agonists with chemotherapy.
  • To discuss future perspectives for this therapeutic approach in bladder cancer.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of apoptotic pathways in cancer chemoresistance.
  • Examination of therapeutic strategies involving apoptosis agonists.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Experiment Videos

Last Updated: Jun 20, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Main Results:

  • Preclinical data suggest that apoptosis agonists can enhance chemotherapy response.
  • Apoptosis modulation is a key factor in overcoming chemoresistance.
  • No clinical trials have yet successfully translated these principles for bladder cancer.

Conclusions:

  • Apoptosis agonists represent a promising strategy to improve bladder cancer prognosis.
  • Combination therapy with conventional chemotherapy warrants further clinical investigation.
  • Targeting apoptotic pathways offers a potential avenue for overcoming treatment resistance in bladder cancer.